Image Description

INVESTORS
& MEDIA

circle

Press Release

  View printer-friendly version

<<  Back

Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to be Presented at the 2009 American Association of Cancer Research Annual Meeting

SOUTH SAN FRANCISCO, CA, Apr 15, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts containing non-clinical data relating to GSK-923295, a novel inhibitor of centromere-associated protein E (CENP-E), are scheduled to be presented at the 2009 American Association of Cancer Research (AACR) Annual Meeting to be held from April 18 - 22, 2009 at the Colorado Convention Center in Denver, CO. One poster will detail findings of a pharmacokinetic assessment of GSK-923295 and the other poster will detail pre-clinical assessments of GSK-923295 in breast cancer cells.

Poster Presentations at the 2009 AACR Annual Meeting:

Abstract #5452: Exploratory Methods for Assessment of Therapeutic Exposures and Schedules of GSK923295A, a Novel Mitotic Checkpoint Inhibitor. (Poster displayed on Wednesday, April 22, 2009, 8:00 AM - 12:00 PM, Mountain Time, Exhibit Hall B-F, Session Title: Pharmacokinetics and Pharmacodynamics of Early Clinical Trials, Poster Section 32, Board #22.)

Abstract #5572: Small Molecular Inhibitor of the Centromere-Associated Protein E (CENP-E), GSK923295A Inhibits Cell Growth in Breast Cancer Cells. (Poster displayed on Wednesday, April 22, 2009, 8:00 AM - 12:00 PM, Mountain Time, Exhibit Hall B-F, Session Title: Novel Agents 4, Poster Section 37, Board #14.)

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac muscle myosin activator, is in Phase II clinical trials for the treatment of heart failure. Amgen Inc. has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercialization participation rights. In April 2008, Cytokinetics announced the selection of a potential drug candidate, CK-2017357, directed towards skeletal muscle contractility which may be developed as a potential treatment for diseases and medical conditions associated with skeletal muscle weakness. In January 2009, Cytokinetics announced the selection of a potential drug candidate directed towards smooth muscle contractility which may be developed as a potential treatment for diseases associated with pulmonary arterial hypertension and bronchoconstriction.

Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two drug candidates that have arisen from this program, ispinesib and SB-743921, each an inhibitor of kinesin spindle protein. In addition, Cytokinetics and GlaxoSmithKline are conducting research and development activities focused on GSK-923295, an inhibitor of centromere-associated protein E.

All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the planned presentations at the AACR Annual Meeting and the potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:

Christopher S. Keenan
Director, Investor & Media Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.